| Drug Name |
Ixazomib |
| Drug ID |
BADD_D01223 |
| Description |
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. |
| Indications and Usage |
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XG03 |
| DrugBank ID |
DB09570
|
| KEGG ID |
D10130
|
| MeSH ID |
C548400
|
| PubChem ID |
25183872
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
63020-078; 63020-400; 63020-230; 63020-079; 63020-080; 63020-390 |
| UNII |
71050168A2
|
| Synonyms |
ixazomib | MLN 9708 | MLN9708 | MLN-9708 | Ninlaro |
